This website uses cookies
Read our Privacy policy and Terms of use for more information.
Long Form Content
May 22, 2024
•
9 min read
AstraZeneca sets $80B by 2023 sales targets, two antibody fundraises totalling $345M, and Eli Lilly gets deeper into radiopharma while Astellas gets into automated cell therapy manufacturing.
May 21, 2024
Cell therapy history was made, FDA approves first two Eylea biosimilars, Gilead's $4.3B liver disease bet yields positive ph3 data, and a trilogy of lung disease positive trial data.
May 20, 2024
6 min read
Bayers posts hot menopause clinical trial results, Moderna wins a major lawsuit against Pfizer-BioNTech, and a molecular glue biotech unsticks some staff
May 17, 2024
10 min read
BMS lands new CAR-T accelerated approval, Roche's $2.7B obesity bet has early win, Eli Lilly leads in revenue growth, and J&J pays $850M for atopic dermatitis biotech.
May 16, 2024
8 min read
A "Uniquity" good company launch, Eisai is aiming for 13-fold sales growth, and massive tariffs on imported Chinese medical supplies
May 15, 2024
Novo Nordisk's winning streak continues, Sands Capital closes a $500M+ life science fund, and a Harvard start-up lands 3 big pharma partners.
May 14, 2024
11 min read
All your Biotech & Pharma news in one daily email
May 13, 2024
May 10, 2024
May 9, 2024
12 min read
May 8, 2024
3 min read
(Usually) All your Biotech & Pharma news in one daily email
May 7, 2024
7 min read
